Following Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European Union

Represents the Fourth Innovus Pharma Product Notification in the
E.U.

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men’s and women’s health
and respiratory diseases, today announced that it has received the CPNP
notification number required to commercialize Diabasens® in all 28
member countries of the European Union. This represents the fourth
Innovus Pharma product to receive CPNP notification in the European
Union in the last few years, the others being for Zestra®, Zestra Glide®
and Sensum+®. The product will be available as an over-the-counter
(“OTC”) or behind the counter product and does not require a
prescription.

“We are pleased to announce the receipt of the CPNP in the European
Union for Diabasens®, our current best-selling product. The clearance to
market the product in Europe follows the recently announced approval
from Health Canada for the relief of neuropathy pain,” said Dr. Bassam
Damaj, President and Chief Executive Officer of Innovus Pharma. “This is
one of several products we have filed in Europe which we expect to
receive the notification to commercialize in the near future.”

The product will be launched initially in France, the United Kingdom,
Italy, Germany and Spain through our Pan-European Amazon® store,
followed by local distributors in the second half of 2019. In addition
to the US, Canada and the European Union, Innovus Pharma is working with
certain regulatory agencies in Japan and throughout certain countries in
Latin America to obtain appropriate marketing authorizations to
eventually launch the product in that country and region.

About Diabasens®

Diabasens® is a Natural Health Product approved by Health Canada for the
relief of neuropathy pain. It is a proprietary formulation to increase
local sensation and blood flow. The product is also commercialized in
the U.S. under the cosmetic classification.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to
OTC.

For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.vesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.xyralid.com;
www.fluticare.com;
www.allervarx.com;
www.apeaz.com;
www.mzssleepingaid.com,
www.novalere.com
and www.diabasens.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the sale of the Diabasens® product in the
European Union, estimated market for its products, and statements about
achieving its other development, growth, commercialization, financial
and staffing objectives. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could
differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company’s
most recent filing on Form S-1, annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC’s website or
without charge from the Company.

Contacts

Randy Berholtz
Innovus Pharma Investor Relations
Tel: +1 858
249 7865
[email protected]